Ionis Pharmaceuticals (IONS) announced that the FDA has granted breakthrough therapy designation to ION582 for the treatment of Angelman syndrome, a rare neurological disease that often presents in infancy and is characterized by profound intellectual disability, impaired communication, motor impairment and debilitating seizures.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IONS:
- Ionis Pharmaceuticals price target raised to $80 from $70 at RBC Capital
- Ionis Pharmaceuticals’ Olezarsen Shows Strong Potential in Billion-Dollar Market, Earning Buy Rating from Analyst
- Why Did IONIS Stock (IONS) Surge to a Four-Year High?
- Cautious Optimism for Ionis Pharmaceuticals Amid Promising Olezarsen Trial Results and Pending Regulatory Hurdles
- Ionis Pharmaceuticals: Balancing Promising Trial Results with Market Uncertainties